View Older Stories View More Recent Stories

Mar 4, 2019 08:00AM Esperion Announces Presentation of Bempedoic Acid Pivotal Phase 3 Study 2 Results in a Late-Breaking Clinical Trial Session at the American College of Cardiology 2019 Scientific Sessions
Feb 28, 2019 04:30PM Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Fourth Quarter and Full Year 2018 Financial Results
Feb 28, 2019 04:30PM Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Fourth Quarter and Full Year 2018 Financial Results
Feb 28, 2019 07:26AM Esperion Therapeutics (ESPR) Submits Two NDAs & Completes Two MAA Validations for Both Bempedoic Acid & Bempedoic Acid / Ezetimibe Combination Tablet
Feb 28, 2019 07:00AM Esperion Announces Submissions of Two NDAs and Official Completion of Two MAA Validations for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet
Feb 28, 2019 07:00AM Esperion Announces Submissions of Two NDAs and Official Completion of Two MAA Validations for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet
Feb 22, 2019 05:30PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Feb 22, 2019 05:30PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 4, 2019 07:04AM Esperion Therapeutics (ESPR) Reports Licensing Agreement with Daiichi Sankyo Europe to Commercialize Bempedoic Acid in Europe
Jan 4, 2019 07:00AM Esperion Announces Agreement with Daiichi Sankyo Europe (DSE) to Commercialize Bempedoic Acid in Europe
Jan 4, 2019 07:00AM Esperion Announces Agreement with Daiichi Sankyo Europe (DSE) to Commercialize Bempedoic Acid in Europe
Jan 2, 2019 04:15PM Esperion to Present at the 37th Annual J.P. Morgan Healthcare Conference
Jan 2, 2019 04:15PM Esperion to Present at the 37th Annual J.P. Morgan Healthcare Conference
Nov 12, 2018 06:19AM Esperion Therapeutics (ESPR) Highlights Late-Breaking Oral Presentation of Final Study 3 Results (1002-046) of Bempedoic Acid
Nov 10, 2018 08:15AM Esperion Announces Late-Breaking Oral Presentation of Final Study 3 Results (1002-046) of Bempedoic Acid at the American Heart Association Scientific Sessions 2018
Nov 10, 2018 08:15AM Esperion Announces Late-Breaking Oral Presentation of Final Study 3 Results (1002-046) of Bempedoic Acid at the American Heart Association Scientific Sessions 2018
Nov 8, 2018 08:00AM Esperion to Participate in Upcoming Investor Conferences
Nov 8, 2018 08:00AM Esperion to Participate in Upcoming Investor Conferences
Nov 1, 2018 04:05PM Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter 2018 Financial Results
Nov 1, 2018 04:05PM Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter 2018 Financial Results
Oct 29, 2018 05:46AM Esperion Therapeutics (ESPR) Reports Complete Phase 3 LDL-C Lowering Development Program of Bempedoic Acid & Positive Cumulative Results
Oct 28, 2018 05:10PM Esperion Announces Completion of Phase 3 LDL-C Lowering Development Program of Bempedoic Acid and Positive Cumulative Results
Oct 28, 2018 05:10PM Esperion Announces Completion of Phase 3 LDL-C Lowering Development Program of Bempedoic Acid and Positive Cumulative Results
Oct 28, 2018 05:00PM Esperion Announces Positive Top-Line Results from Final Pivotal Phase 3 Study of Bempedoic Acid
Oct 28, 2018 05:00PM Esperion Announces Positive Top-Line Results from Final Pivotal Phase 3 Study of Bempedoic Acid
Oct 18, 2018 05:00PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Oct 18, 2018 05:00PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aug 27, 2018 07:01AM Esperion (ESPR) Phase 3 Bempedoic Acid / Ezetimibe Combination Pill Study Met its Key Efficacy Endpoints
Aug 27, 2018 07:00AM Esperion Announces Positive Top-Line Results from Pivotal Phase 3 Bempedoic Acid / Ezetimibe Combination Pill Study
Aug 27, 2018 07:00AM Esperion Announces Positive Top-Line Results from Pivotal Phase 3 Bempedoic Acid / Ezetimibe Combination Pill Study
Aug 27, 2018 05:44AM Esperion Therapeutics (ESPR) Announces Final Results of Phase 3 Long-Term Safety Study of Bempedoic Acid at ESC Congress 2018
Aug 25, 2018 05:45AM Esperion Announces Late-Breaking Oral Presentation of Final Results of Phase 3 Long-Term Safety Study of Bempedoic Acid at the European Society of Cardiology Congress
Aug 25, 2018 05:45AM Esperion Announces Late-Breaking Oral Presentation of Final Results of Phase 3 Long-Term Safety Study of Bempedoic Acid at the European Society of Cardiology Congress
Aug 10, 2018 04:30PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aug 10, 2018 04:30PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aug 2, 2018 07:00AM Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter 2018 Financial Results
Aug 2, 2018 07:00AM Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter 2018 Financial Results
Jul 3, 2018 08:30AM Esperion to Host Analyst and Investor Day Event on July 10
Jul 3, 2018 08:30AM Esperion to Host Analyst and Investor Day Event on July 10
Jun 12, 2018 04:01PM Esperion Announces Late-Breaking Oral Presentation of Full Study 4 Results (1002-048) at the International Symposium on Atherosclerosis
Jun 12, 2018 04:01PM Esperion Announces Late-Breaking Oral Presentation of Full Study 4 Results (1002-048) at the International Symposium on Atherosclerosis
May 30, 2018 09:00AM Esperion to Participate in Fireside Chat at the Jefferies 2018 Global Healthcare Conference
May 30, 2018 09:00AM Esperion to Participate in Fireside Chat at the Jefferies 2018 Global Healthcare Conference
May 29, 2018 09:01AM Esperion Therapeutics (ESPR) Reports Appointment of Jay P. Shepard to Board
May 29, 2018 09:00AM Esperion Announces the Appointment of Jay P. Shepard to Board of Directors
May 29, 2018 09:00AM Esperion Announces the Appointment of Jay P. Shepard to Board of Directors
May 25, 2018 04:30PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 25, 2018 04:30PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 23, 2018 08:15AM Esperion Therapeutics (ESPR) Says Third Pivotal Phase 3 Study of Bempedoic Acid Met Primary Endpoint
May 23, 2018 08:15AM Esperion Announces Third Pivotal Phase 3 Study of Bempedoic Acid Meets Primary Endpoint
View More Recent Stories View Older Stories